Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Coherus: Interchangeability ‘A Melting Ice Cube,’ Price And Supply Key

FDA-Approved Yusimry Biosimilar Device ‘Will Look Nearly Identical’

Executive Summary

Coherus’ manufacturing scale for its Yusimry adalimumab biosimilar means it will “be able to drive the price down and to be able to provide supply guarantees,” management has insisted during a recent investor conference. “We think this will be very, very important.”

You may also be interested in...



'Incorrect' To Assume Interchangeables Are Safer, More Effective Than Biosimilars, Says FDA

US FDA India country director Dr Sarah McMullen provides a fact check at a recent conclave to dispel the notion that interchangeable biosimilars are safer and more effective than other approved biosimilars.

Coherus Shakes Up Ranibizumab Competition With First Interchangeable US Biosimilar

Coherus BioSciences has heralded a “strategic inflection point” for the company after receiving USFDA approval for Cimerli as an interchangeable biosimilar rival to Lucentis. The firm has also revealed launch plans for the Bioeq-partnered ranibizumab product.

US Biosimilar Outlook: Inspections, Interchangeability And Positioning For The Post-Humira Era

Six of the 10 biosimilar candidates under FDA review are waiting on inspections delayed by COVID-19; in the meantime, sponsors jockey for position when Humira biosimilar launch windows open up next year.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB151744

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel